Great West Life Assurance Co. Can bought a new stake in Bausch Health Companies Inc (NYSE:BHC) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 340,030 shares of the company’s stock, valued at approximately $8,737,000. Great West Life Assurance Co. Can owned 0.10% of Bausch Health Companies at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of BHC. Bank of Montreal Can purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at $94,432,000. FIL Ltd purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at $75,624,000. CIBC World Markets Inc. purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at $64,359,000. Chou Associates Management Inc. purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at $42,330,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at $38,497,000. 50.09% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Schutter Richard U. De purchased 125,000 shares of the company’s stock in a transaction that occurred on Thursday, September 13th. The shares were purchased at an average price of $23.96 per share, with a total value of $2,995,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Paul Herendeen purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The shares were purchased at an average cost of $22.61 per share, for a total transaction of $226,100.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 165,000 shares of company stock worth $3,890,700 in the last ninety days. 11.54% of the stock is currently owned by insiders.
A number of equities analysts have recently commented on the stock. Mizuho raised their target price on shares of Bausch Health Companies from $35.00 to $38.00 and gave the company a “buy” rating in a research note on Friday, November 30th. BMO Capital Markets reissued a “hold” rating and issued a $26.00 target price on shares of Bausch Health Companies in a research note on Tuesday, November 13th. ValuEngine downgraded shares of Bausch Health Companies from a “hold” rating to a “sell” rating in a research note on Monday, November 12th. TD Securities raised their target price on shares of Bausch Health Companies from $24.00 to $28.00 and gave the company a “hold” rating in a research note on Wednesday, November 7th. Finally, Royal Bank of Canada raised their target price on shares of Bausch Health Companies from $30.00 to $31.00 and gave the company a “hold” rating in a research note on Wednesday, November 7th. Three analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $28.18.
Bausch Health Companies stock opened at $23.66 on Friday. Bausch Health Companies Inc has a 12-month low of $14.44 and a 12-month high of $28.45. The firm has a market cap of $8.48 billion, a P/E ratio of 6.14, a PEG ratio of 0.32 and a beta of -0.28. The company has a current ratio of 1.14, a quick ratio of 0.91 and a debt-to-equity ratio of 7.55.
Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.84 by $0.31. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The firm had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.09 billion. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. On average, equities analysts expect that Bausch Health Companies Inc will post 3.81 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Great West Life Assurance Co. Can Purchases Shares of 340,030 Bausch Health Companies Inc (BHC)” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/12/08/great-west-life-assurance-co-can-purchases-shares-of-340030-bausch-health-companies-inc-bhc.html.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.